Antonio Rullan
YOU?
Author Swipe
View article: Figure 1 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
Figure 1 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer Open
Locoregional control was maintained or improved with the combination of xevinapant and CRT in vivo in a CD8+ T cell–independent manner. Data presented in this figure were obtained using the mEER model. A, Treatment…
View article: Figure S6 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
Figure S6 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer Open
Comparison of our dataset with published gene signatures predicting immunotherapy responsiveness and prognosis in human SCCHN.
View article: Figure S4 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
Figure S4 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer Open
Schematic of the Nr4a3-Tocky system.
View article: Data from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
Data from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer Open
Xevinapant is an orally bioavailable antagonist of select members of the inhibitor of apoptosis protein family. Despite promising phase II data, combining xevinapant with chemoradiotherapy (CRT) failed to improve outcomes in the phase III …
View article: Supplementary Data from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
Supplementary Data from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer Open
List of anti-mouse monoclonal antibodies used for flow cytometry.
View article: Figure S7 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
Figure S7 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer Open
Flow cytometry gating strategy for immune profiling.
View article: Figure S5 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
Figure S5 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer Open
RNAseq data showing that the addition of xevinapant to CRT does not enhance the immunogenicity of the MOC1 model.
View article: Figure 2 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
Figure 2 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer Open
Xevinapant plus CRT reduced the numbers of cytotoxic CD8+ T cells and NK cells vs. CRT alone; remaining CD8+ T cells are PD-1hi CD38hi and not persistently engaged with antigens. Flow cytometry r…
View article: Figure S3 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
Figure S3 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer Open
In vivo studies of xevinapant in combination with RT or CRT in the MOC1 model.
View article: Figure 4 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
Figure 4 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer Open
Xevinapant plus CRT significantly increased the expression of immunosuppressive acute-phase proteins and enhanced apoptotic rather than necroptotic cell death. Data presented in this figure were performed in the mEER model and treatment re…
View article: Figure S1 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
Figure S1 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer Open
In vitro xevinapant combination with CRT increases MOC1 tumour cell death but not in mEER.
View article: Figure S2 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
Figure S2 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer Open
In vivo studies of xevinapant in combination with RT or CRT in the mEER model.
View article: Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis
Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis Open
Background Immune checkpoint inhibitors (ICIs), particularly anti-PD-(L)1s, have transformed cancer care by their extended efficacy, even receiving next-line. Event-free survival 2 (EFS2), progression/recurrence-free survival 2 (PRFS2) and…
View article: Adjuvant pembrolizumab in high-risk renal cell carcinoma: A tertiary high volume centre experience
Adjuvant pembrolizumab in high-risk renal cell carcinoma: A tertiary high volume centre experience Open
View article: Multicellular Calcium Waves in Cancer-Associated Fibroblasts Regulate Neuronal Mimicry and Anisotropy Leading to Immune Exclusion
Multicellular Calcium Waves in Cancer-Associated Fibroblasts Regulate Neuronal Mimicry and Anisotropy Leading to Immune Exclusion Open
Summary Stromal barriers exclude CD8+ T cells from accessing cancer cells and hamper immune-mediated tumour control. Through multi-pronged analysis of tumours that transition from immune inflamed to immune excluded, we reveal that the form…
View article: Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer Open
Xevinapant is an orally bioavailable antagonist of select members of the inhibitor of apoptosis protein family. Despite promising phase II data, combining xevinapant with chemoradiotherapy (CRT) failed to improve outcomes in the phase III …
View article: Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity
Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity Open
Background We previously showed that oncolytic virotherapy delivered by isolated limb perfusion (ILP), combined with immune checkpoint inhibition, prevents both local tumor progression and systemic metastases in an animal sarcoma model. Me…
View article: Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion Open
View article: Tumor-infiltrating CD27<sup>-</sup>IgD<sup>-</sup> regulatory B cells suppress cytotoxic CD8<sup>+</sup>T cell responses in renal cell carcinoma
Tumor-infiltrating CD27<sup>-</sup>IgD<sup>-</sup> regulatory B cells suppress cytotoxic CD8<sup>+</sup>T cell responses in renal cell carcinoma Open
Summary B cells play a pivotal role in shaping the tumor microenvironment (TME) and tertiary lymphoid structures (TLS), but the functions of specific B cell subsets in cancer pathogenesis remain unclear. Using a novel tissue-centric single…
View article: The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models Open
Reovirus type 3 Dearing (RT3D) is an oncolytic, double-stranded RNA virus. To identify potential RT3D drug-viral sensitizer, here we use a high-throughput screen of therapeutic agents and find a PARP-1 inhibitor, talazoparib, as a top hit.…
View article: BI31 A case of unusual umbilical lichen planus associated with pembrolizumab
BI31 A case of unusual umbilical lichen planus associated with pembrolizumab Open
A 65-year-old White man developed violaceous, scaly, pruritic plaques on the umbilicus and lower back 12 weeks into adjuvant pembrolizumab therapy following nephrectomy for high-risk clear cell renal carcinoma. Initially thought to be psor…
View article: Renal cell carcinoma with cavoatrial ventricular involvement
Renal cell carcinoma with cavoatrial ventricular involvement Open
View article: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion Open
Cytoplasmic pattern recognition receptors (PRR) for double-stranded RNA, such as RIG-I/MDA5, are key mediators of anti-viral responses. Here we screen for synergistic drug-virotherapy combinations and find that the reovirus type III Dearin…
View article: 4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models Open
Background Ionizing radiation (IR) is a double-edged sword for immunotherapy as it may have both immunosuppressive and immunostimulatory effects. The biological effects of IR on the tumor microenvironment (TME) are a key factor for this ba…
View article: A Case of Unusual Umbilical Lichen Planus Associated with Pembrolizumab
A Case of Unusual Umbilical Lichen Planus Associated with Pembrolizumab Open
View article: 781 4–1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models
781 4–1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models Open
View article: Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy
Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy Open
The combination of radiotherapy/chemoradiotherapy and immune checkpoint blockade can result in poor outcomes in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Here, we show that combining ATR inhibition (ATRi…
View article: Cancer cell – Fibroblast crosstalk via HB-EGF, EGFR, and MAPK signaling promotes the expression of macrophage chemo-attractants in squamous cell carcinoma
Cancer cell – Fibroblast crosstalk via HB-EGF, EGFR, and MAPK signaling promotes the expression of macrophage chemo-attractants in squamous cell carcinoma Open
Interactions between cells in the tumor microenvironment (TME) shape cancer progression and patient prognosis. To gain insights into how the TME influences cancer outcomes, we derive gene expression signatures indicative of signaling betwe…
View article: Study of late toxicity biomarkers of locally advanced head and neck cancer patients treated with radiotherapy plus cisplatin or cetuximab points to the relevance of skin macrophages (TOX-TTCC-2015-01)
Study of late toxicity biomarkers of locally advanced head and neck cancer patients treated with radiotherapy plus cisplatin or cetuximab points to the relevance of skin macrophages (TOX-TTCC-2015-01) Open
View article: A comprehensive examination of mental health in patients with head and neck cancer: systematic review and meta-analysis
A comprehensive examination of mental health in patients with head and neck cancer: systematic review and meta-analysis Open
Background Patients with head and neck cancer present particularly considerable levels of emotional distress. However, the actual rates of clinically relevant mental health symptoms and disorders among this population remain unknown. Metho…